• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ovid Therapeutics Inc.

    7/31/23 5:21:08 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OVID alert in real time by email
    SC 13G 1 ovid13g-07242023.htm
    #SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G
    (RULE 13d - 102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
    (Amendment No. )*
    Ovid Therapeutics Inc
    (Name of Issuer)
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
    690469101
    (CUSIP Number)
    July 20, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Madison Avenue International LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    3,609,054
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    3,609,054
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    3,609,054
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.1%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO




    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Madison Avenue Partners, LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    3,609,054
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    3,609,054
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    3,609,054
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.1%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO




    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    EMAI Management, LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    3,609,054
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    3,609,054
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    3,609,054
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.1%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Madison Avenue GP, LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    3,609,054
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    3,609,054
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    3,609,054
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.1%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Caraway Jackson Investments LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    3,609,054
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    3,609,054
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    3,609,054
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.1%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Eli Samaha
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    3,609,054
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    3,609,054
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    3,609,054
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    5.1%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    IN



    Item 1(a).
    Name of Issuer:
    Ovid Therapeutics Inc (“Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    512 Seventh Avenue, New York, New York 10018
    Item 2(a).
    Name of Persons Filing:
    The names of the persons filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are:
    •
    Madison Avenue International LP,

    •
    Madison Avenue Partners, LP,

    •
    EMAI Management, LLC,

    •
    Madison Avenue GP, LLC,

    •
    Caraway Jackson Investments LLC, and

    •
    Eli Samaha.

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
    The principal business address for each of the Reporting Persons is 150 East 58th St, 14th Fl, New York, NY 10155.
    Item 2(c).
    Citizenship:
    Madison Avenue International LP is a Cayman Islands exempted limited partnership. Madison Avenue Partners, LP is a Delaware limited partnership. Each of EMAI Management, LLC, Madison Avenue GP, LLC and Caraway Jackson Investments LLC is a Delaware limited liability company. Mr. Samaha is a citizen of the United States of America.
    Item 2(d).
    Title of Class of Securities:
    Common Stock, par value $ $0.001 per share (the “Common Stock”)
    Item 2(e).
    CUSIP Number:
    690469101
    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
           
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
           
     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.


           
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
           
     
    (e)
    [x]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4.
    Ownership.
    (a)
    Amount beneficially owned:
    As of July 31, 2023, Madison Avenue International LP beneficially owned 3,609,054 shares of Common Stock.
    Madison Avenue Partners, LP and Madison Avenue GP, LLC, as the investment manager and general partner of Madison Avenue International LP, respectively, may be deemed to be the beneficial owner of the shares of Common Stock owned directly by Madison Avenue International LP.
    EMAI Management, LLC, as the general partner of Madison Avenue Partners, LP, may be deemed to be the beneficial owner of the shares of Common Stock owned directly by Madison Avenue International LP.
    Caraway Jackson Investments LLC, as the owner of Madison Avenue GP, LLC, may be deemed to be the beneficial owner of the shares of Common Stock owned directly by Madison Avenue International LP.
    Mr. Samaha, as the non-member manager of Madison Avenue GP, LLC, the managing member of EMAI Management, LLC, and the majority owner of Caraway Jackson Investments LLC, may be deemed to be the beneficial owner of the shares of Common Stock owned by Madison Avenue International LP.
    (b)
    Percent of Class:
    The following percentage is based on 70,521,340 shares of Common Stock outstanding as of May 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 5, 2023.
    As of July 20, 2023, the Reporting Persons may be deemed to have beneficially owned approximately 5.1% of the outstanding shares of Common Stock.
    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote of shares of Common Stock:
    See Cover Pages Items 5-9.


    (ii)
    Shared power to vote or to direct the vote of shares of Common Stock:
    See Cover Pages Items 5-9.

    (iii)
    Sole power to dispose or to direct the disposition of shares of Common Stock:
    See Cover Pages Items 5-9.

    (iv)
    Shared power to dispose or to direct the disposition of shares of Common Stock:
    See Cover Pages Items 5-9.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit A.
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
    Item 10.
    Certification.
    By signing below the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
    Dated: July 31, 2023
    MADISON AVENUE INTERNATIONAL LP
    By: Madison Avenue GP, LLC, its general partner


    By: /s/ Eli Samaha                                                      
        Eli Samaha, as Manager


    MADISON AVENUE PARTNERS, LP
    By: EMAI Management, LLC, its general partner


    By: /s/ Eli Samaha                                                      
        Eli Samaha, as Managing Member


    EMAI MANAGEMENT, LLC


    By: /s/ Eli Samaha                                                      
        Eli Samaha, as Managing Member


    MADISON AVENUE GP, LLC


    By: /s/ Eli Samaha                                                      
        Eli Samaha, as Manager


    CARAWAY JACKSON INVESTMENTS, LLC


    By: /s/ Eli Samaha                                                      
        Eli Samaha, as Member


    /s/ Eli Samaha                                                                      
    ELI SAMAHA

    *The Reporting Persons disclaim beneficial ownership in the Common Stock reported herein except to the extent of their pecuniary interest therein.
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
    Note.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.
    Attention.  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

    EXHIBIT A
    JOINT FILING AGREEMENT
    The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of Common Stock of Ovid Therapeutics Inc dated as of July 31, 2023 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
    Dated: July 31, 2023
    MADISON AVENUE INTERNATIONAL LP
    By: Madison Avenue GP, LLC, its general partner


    By: /s/ Eli Samaha
        Eli Samaha, as Manager


    MADISON AVENUE PARTNERS, LP
    By: EMAI Management, LLC, its general partner


    By: /s/ Eli Samaha
        Eli Samaha, as Managing Member


    EMAI MANAGEMENT, LLC


    By: /s/ Eli Samaha
        Eli Samaha, as Managing Member


    MADISON AVENUE GP, LLC


    By: /s/ Eli Samaha
        Eli Samaha, as Manager


    CARAWAY JACKSON INVESTMENTS, LLC


    By: /s/ Eli Samaha
        Eli Samaha, as Member


    /s/ Eli Samaha
    Eli Samaha
    Get the next $OVID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OVID

    DatePrice TargetRatingAnalyst
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    12/21/2023$11.00Buy
    BTIG Research
    10/13/2023$8.00Outperform
    Oppenheimer
    8/25/2021$4.50 → $4.00Neutral
    Citigroup
    More analyst ratings

    $OVID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at  investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da

      4/2/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of

      3/11/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Leadership Updates

    Live Leadership Updates

    See more
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

      NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ

      8/8/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

      Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d

      7/23/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    SEC Filings

    See more
    • SEC Form 8-K filed by Ovid Therapeutics Inc.

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:14:40 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Ovid Therapeutics Inc.

      PRE 14A - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:09:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Ovid Therapeutics Inc.

      10-K/A - Ovid Therapeutics Inc. (0001636651) (Filer)

      4/30/25 4:06:12 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 6:01:44 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 4:39:42 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/14/24 4:15:31 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      1/29/25 9:18:08 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/20/24 5:22:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $OVID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ovid Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform

      6/18/24 7:38:14 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Ovid Therapeutics with a new price target

      B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/30/24 8:03:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ovid Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/29/24 7:56:55 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Papadopoulos Stelios

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:44:34 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Papadopoulos Stelios claimed ownership of 200,000 shares (SEC Form 3)

      3 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:42:41 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBFO Rona Jeffrey A sold $2,185 worth of shares (3,902 units at $0.56), decreasing direct ownership by 5% to 67,973 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/28/25 4:15:08 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care